1BSX Stock Overview
Develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Boston Scientific Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$89.00 |
| 52 Week High | US$102.00 |
| 52 Week Low | US$63.50 |
| Beta | 0.73 |
| 1 Month Change | -9.18% |
| 3 Month Change | 1.14% |
| 1 Year Change | 41.27% |
| 3 Year Change | 116.73% |
| 5 Year Change | 171.59% |
| Change since IPO | 132.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1BSX | IT Medical Equipment | IT Market | |
|---|---|---|---|
| 7D | -5.3% | -2.2% | -1.3% |
| 1Y | 41.3% | 1.7% | 10.6% |
Return vs Industry: 1BSX exceeded the Italian Medical Equipment industry which returned 1.7% over the past year.
Return vs Market: 1BSX exceeded the Italian Market which returned 10.6% over the past year.
Price Volatility
| 1BSX volatility | |
|---|---|
| 1BSX Average Weekly Movement | 4.0% |
| Medical Equipment Industry Average Movement | 5.6% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in IT Market | 8.2% |
| 10% least volatile stocks in IT Market | 2.7% |
Stable Share Price: 1BSX has not had significant price volatility in the past 3 months compared to the Italian market.
Volatility Over Time: 1BSX's weekly volatility (4%) has been stable over the past year.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1979 | 53,000 | Mike Mahoney | www.bostonscientific.com |
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention portfolios; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, proprietary programming software, radiofrequency ablation, indirect decompression systems, and intraosseous nerve ablation and deep brain stimulation systems.
Boston Scientific Corporation Fundamentals Summary
| 1BSX fundamental statistics | |
|---|---|
| Market cap | €134.28b |
| Earnings (TTM) | €1.68b |
| Revenue (TTM) | €15.20b |
78.6x
P/E Ratio8.7x
P/S RatioIs 1BSX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1BSX income statement (TTM) | |
|---|---|
| Revenue | US$16.75b |
| Cost of Revenue | US$5.29b |
| Gross Profit | US$11.46b |
| Other Expenses | US$9.60b |
| Earnings | US$1.85b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Apr 23, 2025
| Earnings per share (EPS) | 1.25 |
| Gross Margin | 68.41% |
| Net Profit Margin | 11.06% |
| Debt/Equity Ratio | 48.3% |
How did 1BSX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/03 23:22 |
| End of Day Share Price | 2025/04/03 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Boston Scientific Corporation is covered by 67 analysts. 32 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| David Rescott | Baird |
| Matt Miksic | Barclays |